Stocklytics Platform
Asset logo for symbol RANI
Rani Therapeutics Holdings
RANI45
$1.40arrow_drop_up8.07%$0.10
Penny Stock
Asset logo for symbol RANI
RANI45

$1.40

arrow_drop_up8.07%

Performance History

Chart placeholder
Key Stats
Open$1.31
Prev. Close$1.30
EPS-1.05
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$46.63M
PE Ratio-
LOWHIGH
Day Range1.30
1.42
52 Week Range1.30
8.75
Ratios
Revenue-
EBITDA Margin %-
EPS-1.05

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Rani Therapeutics Holdings (RANI)

Rani Therapeutics Holdings, Inc. (RANI) is a medical technology company that specializes in developing innovative solutions for oral drug delivery. The company is focused on revolutionizing the way biologics and other high-value therapeutics are administered to patients. Rani Therapeutics has developed a unique pill that can deliver drugs directly into the bloodstream, bypassing the stomach and avoiding the need for injections. The technology behind the pill is based on the concept of the robotically controlled needle, which can inject drugs into the intestinal wall. This approach has the potential to improve patient compliance and enhance drug absorption.
Rani Therapeutics has been making significant progress in its mission to transform drug delivery. The company recently announced positive results from its Phase 1 clinical trial for its lead product candidate, RaniPill. The trial demonstrated that the RaniPill was safe and well-tolerated in healthy volunteers. The success of the trial is a major milestone for the company and paves the way for further development and commercialization of the technology. Rani Therapeutics plans to initiate Phase 2 studies to evaluate the efficacy of the RaniPill in specific therapeutic areas.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Talat Imran
Headquarters
San Jose
Employees
163
Exchange
NASDAQ
add Rani Therapeutics Holdings to watchlist

Keep an eye on Rani Therapeutics Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Rani Therapeutics Holdings's (RANI) price per share?

The current price per share for Rani Therapeutics Holdings (RANI) is $1.4. The stock has seen a price change of $0.1 recently, indicating a 8.08% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Rani Therapeutics Holdings (RANI)?

For Rani Therapeutics Holdings (RANI), the 52-week high is $8.75, which is 525% from the current price. The 52-week low is $1.3, the current price is 7.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Rani Therapeutics Holdings (RANI) a growth stock?

Rani Therapeutics Holdings (RANI) has shown an average price growth of -4.97% over the past three years. It has received a score of -1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Rani Therapeutics Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Rani Therapeutics Holdings (RANI) stock price performance year to date (YTD)?

As of the latest data, Rani Therapeutics Holdings (RANI) has a year-to-date price change of -58.46%. Over the past month, the stock has experienced a price change of -31.37%. Over the last three months, the change has been -35.78%. Over the past six months, the figure is -66.27%.
help

Is Rani Therapeutics Holdings (RANI) a profitable company?

Rani Therapeutics Holdings (RANI) has a net income of -$33.97M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$66.1M. Furthermore, the EBITDA is -$56.9M.
help

What is the market capitalization of Rani Therapeutics Holdings (RANI)?

Rani Therapeutics Holdings (RANI) has a market capitalization of $46.64M. The average daily trading volume is 1.37, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level